ANI Pharmaceuticals, Inc. (ANIP)

ANI Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	360.21	285.59	144.86	221.12	48.23	100.3
Short-Term Investments	15.63	9.13	6.31	-	-	-
Cash & Short-Term Investments	376.96	294.72	151.17	221.12	48.23	100.3
Cash Growth	68.65%	94.96%	-31.64%	358.49%	-51.92%	1175.43%
Receivables	274.47	281.08	221.73	162.08	165.44	128.53
Inventory	143.15	143.07	136.78	111.2	105.36	81.69
Prepaid Expenses	30.62	22.99	17.98	17.4	8.39	7.59
Restricted Cash	0.04	0.04	0.03	-	5.01	-
Other Current Assets	0.2	11.23	0.77	8.02	11.85	3.67
Total Current Assets	825.43	753.12	528.46	519.82	344.26	321.78
Property, Plant & Equipment	73.22	62.48	56.86	44.59	43.25	52.67
Long-Term Investments	-	1.65	4.9	6.24	8.8	-
Goodwill	62.48	62.48	59.99	28.22	28.22	27.89
Other Intangible Assets	449.86	479.53	541.83	209.01	251.64	294.12
Long-Term Deferred Tax Assets	71.5	69.07	85.11	90.71	81.36	67.94
Long-Term Deferred Charges	0.5	0.6	-	-	-	-
Other Long-Term Assets	11.12	11.46	7.32	5.84	2.56	7.21
Total Assets	1,494	1,440	1,284	904.42	760.09	771.6

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	73.83	62.58	45.66	36.68	29.31	22.97
Accrued Expenses	140.95	144.32	92.8	57.84	35.89	27.89
Current Portion of Long-Term Debt	21.33	17.27	9.17	0.85	0.85	0.85
Current Portion of Leases	-	2.03	-	-	-	-
Current Income Taxes Payable	3.53	2.24	7.52	8.16	-	-
Other Current Liabilities	44.01	49.67	39.3	41.94	33.4	35.83
Total Current Liabilities	283.66	278.11	194.45	145.48	99.44	87.54
Long-Term Debt	589.16	599.77	614.92	284.82	285.67	286.52
Long-Term Leases	15.54	9.22	-	-	1.38	-
Other Long-Term Liabilities	8.55	12.55	46.57	16.53	35.06	38.8
Total Liabilities	896.9	899.65	855.94	446.82	421.55	412.86

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	620.25	596.04	519.65	514.1	403.9	387.84
Retained Earnings	31.1	-23.1	-100.28	-80.13	-97.29	-47.77
Treasury Stock	-53.82	-33.25	-21.04	-10.08	-5.09	-3.14
Comprehensive Income & Other	-0.33	1.03	5.34	8.86	12.17	-3.06
Total Common Equity	597.21	540.72	403.68	432.75	313.69	333.89
Shareholders' Equity	597.21	540.72	428.53	457.6	338.54	358.74
Total Liabilities & Equity	1,494	1,440	1,284	904.42	760.09	771.6

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	626.03	628.28	624.09	285.67	287.9	287.37
Net Cash (Debt)	-249.07	-333.57	-472.92	-64.55	-239.67	-187.07
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-11.30	-15.71	-24.48	-3.55	-14.74	-14.85
Filing Date Shares Outstanding	21.43	20.88	20.31	19.72	16.35	16.55
Total Common Shares Outstanding	21.43	20.95	19.65	19.12	16.35	16.12
Working Capital	541.78	475.01	334	374.34	244.82	234.24
Book Value Per Share	27.87	25.80	20.54	22.64	19.18	20.71
Tangible Book Value	84.88	-1.28	-198.14	195.52	33.83	11.88
Tangible Book Value Per Share	3.96	-0.06	-10.08	10.23	2.07	0.74
Land	-	2.41	1.58	1.55	1.55	5.95
Buildings	-	25.83	24.44	17.88	16.66	19.97
Machinery	-	76.04	68.7	50.41	53.15	46.77
Construction In Progress	-	8.83	4.57	7.69	4.6	2.94
Leasehold Improvements	-	1.41	1.3	-	-	-

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 7, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 28, 2026

Data Sources Report a data error